Genetic Surveillance of SARS-CoV-2 Mpro Reveals High Sequence and Structural Conservation Prior to the Introduction of Protease Inhibitor Paxlovid
Article
[키워드] 3CLpro
acute respiratory syndrome
Analysis
analyzed
Antiviral
antiviral drug
Antiviral treatment
antivirals
baseline
binding
circulating
cleavage
clinical response
conservation
conserved
Contact
Coronaviral
Coronaviridae family
coronavirus
COVID-19
COVID-19 pandemic
Critical
database
determine
drug target
effort
Emergency use authorization
enzyme
escape mutation
EUA
Evolution
expected
Genetic
genomic
GISAID
globe
health emergency
implication
inhibitor
inhibitors
initiative
introduced
isolate
isolates
M pro
motifs
MPro
Mutation
Nirmatrelvir
pandemic progresse
Paxlovid
protease
purifying selection
raise
reference sequence
Region
remained
residue
retrieved
robust
SARS-CoV-2
SARS-CoV-2 genome
SARS-CoV-2 Mpro
SARS-CoV-2 viral
selective
sequence
Sequencing
starting point
Surveillance
the SARS-CoV-2
the spike protein
Treatment
unique
variants
variants of SARS-CoV-2
virus
widespread
Wuhan-Hu-1
[DOI] 10.1128/mbio.00869-22 PMC 바로가기
[DOI] 10.1128/mbio.00869-22 PMC 바로가기